Earlier this year, leqembi (a drug that slows memory decline for those in the early stages of Alzheimer’s Disease by targeting the amyloid protein, usually common with those inflicted with Alzheimer’s as it begins to form) was approved by both FDA and CMS (governmental assistance...
A milestone event in the fight against Alzheimer’s Disease occurred on July 6 when the FDA gave approval for a drug (Leqembi) that not only slows memory loss for those with Alzheimer’s Disease, but it was granted funding approval by the Centers for Medicare &...
The Senate Labor-HHS Appropriations Subcommittee has proposed a $350 million increase, raising the total to $2.8 billion annually if passed into law, for research funding on Alzheimer’s and dementia for year 2020. The Senate Subcommittee saw the progress in dementia research being made by researchers...
